author-photo

Constantine S. Tam

Peter MacCallum Cancer Centre
St. Vincent's Health System
University of Melbourne

495

Papers

11450

Citations

Citation Trend

Filter By

Papers (495) Sort By

Journal Conference Others

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

2021
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (0)
Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

2021
- Constantine S. Tam
Show All
- Source
- Cite
- Save
Citations (0)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (5)
Real World Data on the Outcomes of Richter’s Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Use of venetoclax combination regimens in chronic lymphocytic leukemia.

2021 Clinical advances in hematology & oncology
- Constantine S. Tam
Show All
- Source
- Cite
- Save
Citations (0)